Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
FOLD | US
0.01
0.09%
Healthcare
Biotechnology
30/06/2024
04/10/2024
10.60
10.62
10.68
10.46
Amicus Therapeutics Inc. a biotechnology company focuses on discovering developing and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia Pennsylvania.
View LessLow Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Midcap (2B - 10B USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
22.4%1 month
21.6%3 months
37.6%6 months
37.7%-
47.85
23.97
3.35
0.59
-35.99
7.38
-0.18
-16.68M
3.14B
3.14B
-
11.82
-
34.00
-97.94
11.11
7.74
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.97
Range1M
1.47
Range3M
2.83
Rel. volume
0.64
Price X volume
14.39M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
TG Therapeutics Inc | TGTX | Biotechnology | 22.23 | 3.44B | -0.67% | 35.04 | 63.38% |
Apellis Pharmaceuticals Inc | APLS | Biotechnology | 27.51 | 3.35B | -3.41% | n/a | 179.52% |
Dynegy Inc | DYN | Biotechnology | 32.58 | 3.27B | -8.35% | n/a | 3.32% |
Iovance Biotherapeutics Inc | IOVA | Biotechnology | 10.46 | 3.17B | 7.17% | n/a | 10.63% |
Xenon Pharmaceuticals Inc | XENE | Biotechnology | 40.73 | 3.09B | -0.27% | n/a | 1.19% |
Rhythm Pharmaceuticals Inc | RYTM | Biotechnology | 49.63 | 3.03B | -2.71% | n/a | 642.15% |
Kymera Therapeutics Inc | KYMR | Biotechnology | 43.06 | 2.83B | -4.31% | n/a | 12.87% |
PTC Therapeutics Inc | PTCT | Biotechnology | 35.1 | 2.70B | -3.65% | n/a | -40.35% |
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.4 | 2.66B | 4.18% | n/a | 0.98% |
Zai Lab Limited | ZLAB | Biotechnology | 26.36 | 2.63B | 2.93% | n/a | 11.88% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -35.99 | 0.76 | Cheaper |
Ent. to Revenue | 7.38 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 23.97 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 37.58 | 74.67 | Lower Risk |
Debt to Equity | 3.35 | -1.82 | Expensive |
Debt to Assets | 0.59 | 0.26 | Expensive |
Market Cap | 3.14B | 3.73B | Par |